Monitoring changes in bone density

Women's Health

Volumn 4, Issue 1, 2008, Pages 89-97

  Bonnick, Sydney Lou ^a  

^a Clinical Research Center of North Texas   (United States)

Author keywords

BMD; Bone density; Densitometry; DXA; Osteoporosis; Precision; Repeatability

Indexed keywords

ALENDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN;

ACCURACY; BONE DENSITY; BONE STRENGTH; CLINICAL TRIAL; DENSITOMETRY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SPINE FRACTURE; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY; FEMALE; FRACTURES, BONE; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; MONITORING, PHYSIOLOGIC; OSTEOPOROSIS; RISK FACTORS;

EID: 38049121077     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.1.89     Document Type: Review

References (40)

1. Heaney RP: BMD: the problem. Osteoporus. Int. 16(9), 1013-1015 (2005).
2. Wasnich RD, Ross PD, Davis JW, Vogel JM: A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J Nucl. Med. 30(7), 1166-1171 (1989).
3. Hui SL, Slemenda CW, Johnston CC Jr: Baseline measurement of bone mass predicts fracture in white women. Ann. Intern. Med. 111(5), 355-361 (1989).
4. Gardsell P, Johnell O, Nilsson BE: The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif. Tissue Int. 49(2), 90-94 (1991).
5. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W: Axial and appendicular bone density predict fractures in older women. J. Bone Miner. Res. 7(6), 633-638 (1992).
6. Melton LJ, III, Atkinson, EJ, O'Fallon WM, Wahner HW Riggs BL: Long-term fracture prediction by bone mineral assessed at different skeletal sites. J. Bone Miner. Res. 8(10), 1227-1233 (1993).
7. Cummings SR, Black DM, Nevitt MC et al.: Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lance 341(8837), 72-75 (1993).
8. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041), 1254-1259 (1996).
9. Cummings SR, Black DM, Thompson DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24), 2077-2082 (1998).
10. Black DM, Cummings SR, Karpf DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041), 1535-1541 (1996).
11. Ettinger B, Black DM, Mitiak BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637-645 (1999).
12. Harris ST, Watts NB, Genant HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14), 1344-1352 (1999).
13. Reginster J, Minne HW, Sorensen OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11(1), 83-91 (2000).
14. Chesnut CH, III, Silverman S, Andriano K et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109(4), 267-276 (2000).
15. Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J. Clin. Endocrinol. Metab 85(1), 231-236 (2000).
16. Cummings SR, Karpf DB, Harris F et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 112(4), 281-289 (2002).
17. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17(1), 1-10 (2002).
18. Li Z, Meredith MP, Hoseyni MS: A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat. Med. 20(21), 3175-3188 (2001).
19. Watts NB, Cooper C, Lindsay R et al.: Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J. Clin. Densitom. 7(3), 255-261 (2004).
20. Shih J, Bauer DC, Orloff J et al.: Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors. Osteoporos. Int. 13(S3), S38-S39 (2007).
21. Chapurlat RD, Palermo L, Ramsay P, Cummings SR: Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 16(7), 842-848 (2005).
22. Hochberg MC, Ross PD, Black D et al.: Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures, in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis. Rheum. 42(6). 1246-1254 (1999).
23. Watts NB, Cooper C, Lindsay R et al.: Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin. Densitom. 7(3), 255-261 (2004).
24. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH: Bone response to treatment With lower doses of conjugated estrogens with and without medroxyprogesterone, acetate in early postmenopausal women. Osteoporos. Int. 16(4), 372-379 (2005).
25. Luckey M, Kagan R, Greenspan S et al.: Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 11(4), 405-415 (2004).
26. Bonnick S, Saag KG, Kiel DP et al.: Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J. Clin. Endocrinol. Metab. 91(7), 2631-2637 (2006).
27. Recker RR, Luckey M, Stakkestad JA et al.: Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE. J. Bone Miner. Res. 20(S1), S395-S395 (2007).
28. International Organization for Standardization: Accuracy (Trueness and Precision) of Measurement Methods and Results - part 1: General Principles and Definitions. ISO, Geneva, Switzerland 5725-1:1994 E, 1-17 (1994).
29. Engelke K, Glüer CC: Quality and performance measures in bone densitometry. Part 1: Errors and diagnosis. Osteoporos. Int. 17(9), 1283-1292 (2006).
30. Lenchik L, Kiebzak GM, Blunt BA: What is the role of serial bone mineral density measurements in patient management? J Clin. Densitom. 5(Suppl.) S29-S38 (2002).
31. Bonnick SL, Johnston CC Jr, Kleerekoper M et al.: Importance of precision in bone density measurements. J. Clin. Densitom. 4(2), 105-110 (2001).
32. Glüer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant H K: Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos. Int. 5(4), 262-270 (1995).
33. Leslie WD, Moayyeri A: Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring. Osteoporos. Int. 17 (11), 1673-1680 (2006).
34. Blake GM, Wahner HW, Fogelman I: Assessment of instrument performance: precision, installation of new equipment and radiation dose. In: The Evaluation of Osteoporosis: Dual Energy X-ray Absorptiometry and Ultrasound in Clinical Practice. Martin Dunitz Ltd, London, UK, 147-172 (1999).
35. Bonnick SL: Bone Densitometry in Clinical Practice: Application and Interpretation. Humana Press, NJ, USA, 1-410 (2004).
36. Hodgson SF, Watts NB, Bilezikian JP et al.: American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr. Pract. 7(4), 293-312 (2001).
37. Hodgson SF, Watts NB, Bilezikian JP et al.: American Association of Clinical Endocrinologists Medical Guidelines for Cinical Practice for the Prevention and Treatment of Postmenopausal Osteoporosis: 2001 edition, with selected updates for 2003. Endocr. Pract. 9(6), 544-564 (2003).
38. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 9(2), 84-101 (2002).
39. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 13(3), 340-367 (2006).
40. Lewiecki EM: Nonresponders to osteoporosis therapy. J. Clin. Densitom. 6(4), 307-314 (2003).